SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

AstraZeneca rises on entering into distribution services agreement with Sun Pharma

02 Jun 2015 Evaluate

Astrazeneca Pharma India is currently trading at Rs. 964.00, up by 4.15 points or 0.43% from its previous closing of Rs. 959.85 on the BSE.

The scrip opened at Rs. 972.55 and has touched a high and low of Rs. 974.70 and Rs. 946.55 respectively. So far 973 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 1245.00 on 23-Jun-2014 and a 52 week low of Rs. 785.30 on 17-Dec-2014.

Last one week high and low of the scrip stood at Rs. 1015.85 and Rs. 850.00 respectively. The current market cap of the company is Rs. 2420.00 crore.

The promoters holding in the company stood at 75.00% while Institutions and Non-Institutions held 15.69% and 9.31% respectively.

AstraZeneca Pharma India (AZPIL) has entered into a distribution services agreement with Sun Pharmaceutical Industries for AstraZeneca’s brand ‘Axcer’, a new brand of ticagrelor, a drug used for the treatment of acute coronary syndrome (ACS).

AZPIL already has a brand under the trademark ‘Brilinta’, for ticagrelor molecule, launched and marketed by AZPIL in India since 2012.

Sun Pharma will be promoting and distributing ‘Axcer’ brand in India. This collaboration enables AstraZeneca to expand usage of this molecule through wider reach to physicians and thereby benefiting a greater number of ACS patients. It strengthens Sun Pharma’s cardiology portfolio with the addition of a new patented therapy. 

 

Astrazeneca Pharma I Share Price

8508.80 -16.30 (-0.19%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×